DAI Zhongqiu , ZHANG Yuwei , Deng Jin , CHEN Zhixing , WU Siying , LIU Ya , DENG Jielun , XIE Yi
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
XIE Yi, Email: xie_yi_77@163.com
Mycobacterium tuberculosis; Drug susceptibility testing; Drug resistance rate
10.7507/1002-0179.201807044
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

ObjectiveTo understand the drug resistance of Mycobacterium tuberculosis complex in West China Hospital, Sichuan University, analyze its drug resistance characteristics, and provide reference for the monitoring of drug-resistant tuberculosis.MethodsFrom January 2016 to March 2018, Mycobacterium tuberculosis drug susceptibility testing kit was used to detect the drug susceptibility of Mycobacterium tuberculosis culture-positive strains in Department of Laboratory Medicine, West China Hospital, Sichuan University. The tested drugs included four of the first-line anti-tuberculosis drugs: rifampicin, isoniazid, ethambutol, and streptomycin, and ten of the second-line anti-tuberculosis drugs: capreomycin, ofloxacin, ethionamide, p-aminosalicylic acid, levofloxacin, moxifloxacin, rifabutin, amikacin, kanamycin, and chlorine phenazine.ResultsA total of 130 patients (130 strains) were enrolled, including 82 newly diagnosed patients (82 strains) and 48 re-treated patients (42 strains). The drug resistance rate of the 130 patients was 37.69%. The drug resistance rate of the newly diagnosed patients (28.05%) was significantly lower than that of the re-treated patients (54.17%), and there was a statistical difference (χ2=8.794, P=0.003). The multi-drug resistance rate of the newly diagnosed patients (6.10%) was significantly lower than that of the re-treated patients (25.00%), and the difference was statistically significant (χ2=9.517, P=0.002). The resistance rate of isoniazid, rifampicin, and streptomycin in newly diagnosed patients (23.17%, 8.54%, and 7.32%, respectively) were significantly lower than those in the re-treated patients (45.83%, 41.67%, and 29.17%, respectively), and the differences were statistically significant (P<0.05). The resistance rate of ofloxacin, moxifloxacin, rifabutin and ethionamide in the newly diagnosed patients (9.76%, 8.54%, 7.31%, and 4.88%, respectively) were significantly lower than those in the re-treated patients (39.58%, 27.08%, 25.00%, and 22.92%, respectively), and the differences were statistically significant (P<0.05).ConclusionIt is necessary to strengthen the standardized treatment of patients with newly diagnosed tuberculosis, increase the treatment and management of re-treated tuberculosis patients, and prevent the generation and spread of drug-resistant patients, especially multidrug-resistant patients.

Citation： DAI Zhongqiu, ZHANG Yuwei, Deng Jin, CHEN Zhixing, WU Siying, LIU Ya, DENG Jielun, XIE Yi. Analysis of drug resistance of Mycobacterium tuberculosis in West China Hospital of Sichuan University from 2016 to 2018 . West China Medical Journal, 2018, 33(8): 984-988. doi: 10.7507/1002-0179.201807044 Copy

  • Previous Article

    Diagnostic value of serum proteomic assay for pulmonary tuberculosis: evidence from a Meta-analysis

  • Next Article

    Expression, purification, and some enzymatic properties of His-tagged recombinant Candida utilis uricase